Claims for Patent: 7,060,687

Summary for Patent: 7,060,687

Title:	Live vaccines for allergy treatment
Abstract:	The invention relates to transformed bacteria of the genus Lactobacillus or Streptococcus, the bacteria having a DNA molecule that includes (1) a nucleotide sequence that encodes a protein allergen and (2) a promoter operably linked to the nucleotide sequence.
Inventor(s):	Hsu; Ching-Hsiang (Taibao, TW), Charng; Yuh-Chyang (Taipei, TW)
Assignee:	Genmont Biotechnology Co. (Chiayi, TW)
Application Number:	09/778,672
Patent Claims:	1. A method of decreasing the production of IgE in a subject exposed to a dust mite allergen, the method comprising: orally administering to the subject a non-pathogenic, Gram-positive bacterium that comprises (i) a nucleotide sequence that encodes a dust mite allergen and (ii) a promoter operably linked to the nucleotide sequence, wherein the promoter is functional in the non-pathogenic, Gram-positive bacterium; and thereby expressing the allergen in the non-pathogenic, Gram-positive bacterium while said bacterium is in the subject in an amount sufficient to suppress an allergen-specific IgE production in the subject upon subsequent exposure to the allergen. 2. The method of claim 1 in which the bacterium is of the genus Lactobacillus, Streptococcus, or Bifidobaterium. 3. The method of claim 2 in which the bacterium is of the genus Lactobacillus. 4. The method of claim 3 in which the bacterium is Lactobacillus acidophilus. 5. The method of claim 1 in which the dust mite allergen is an allergen of Dermatophagoides pteronyssinus, D. farinae, D. microceras, Tyrophagus putesentiae, Lepidoglyphus domesticus, L. destructor, Acarus siro, Euroglyphus maynei, or Biomia tropicali. 6. The method of claim 5 in which the dust mite allergen is an allergen of Dermatophagoides pteronyssinus. 7. The method of claim 1, wherein the allergen is a protein allergen. 8. The method of claim 1, wherein the allergen is a Der p 5 allergen. 9. The method of claim 6 in which the allergen is Der p 5. 10. The method of claim 1, wherein the promoter is a constitutive promoter. 11. The method of claim 3, wherein the bacterium is administered in a yogurt. 12. A method of decreasing the production of IgE in a subject exposed to a dust mite allergen, the method comprising: orally administering to of subject a lactic acid bacterium that expresses a dust mite allergen; and thereby expressing the allergen in the lactic acid bacterium while the lactic acid bacterium is in the subject in an amount sufficient to suppress an allergen-specific IgE production in the subject upon subsequent exposure to the allergen. 13. The method of claim 12 in which the dust mite allergen is an allergen of Dermatophagoides pteronyssinus, D. farinae, D. microceras, Tyrophagus putesentiae, Lepidoglyphus domesticus, L. destructor, Acarus siro, Euroglyphus maynei, or Biomia tropicali. 14. The method of claim 12 in which the dust mite allergen is an allergen of dust mite of Dermatophagoides genus. 15. The method of claim 12 in which the bacterium belongs to the Lactobacillus genus. 16. The method of claim 15 in which the bacterium is administered as a yogurt composition. 17. The method of claim 12 in which the subject is a human subject. 18. A method of decreasing the production of IgE in a subject exposed to a protein aeroallergen, the method comprising: orally administering to the subject a non-pathogenic, Gram-positive bacterium that comprises (i) a nucleotide sequence that encodes a protein aeroallergen and (ii) a promoter operably linked to the nucleotide sequence, wherein the promoter is functional in a bacterial cell; and thereby expressing the protein aeroallergen in the non-pathogenic, Gram-positive bacterium while said bacterium is in the subject in an amount sufficient to suppress an aeroallergen-specific IgE production in the subject upon subsequent exposure to the protein aeroallergen. 19. A method of alleviating bronchopulmonary congestion in a subject exposed to a dust mite allergen, the method comprising: orally administering to the subject a lactic acid bacterium that expresses a dust mite allergen; and thereby expressing the allergen in the lactic acid bacterium while the lactic acid bacterium is in the subject in an amount sufficient to alleviate bronchopulmonary congestion in the subject upon subsequent exposure to the dust mite allergen. 20. The method of claim 19 in which the bacterium belongs to the Lactobacillus genus, and the dust mite allergen is Dermatophagoides pteronyssinus. 21. The method of claim 1, 3, 4, or 6 wherein the promoter is the erythromycin resistance gene promoter, IdhL promoter, or P25 promoter. 22. The method of claim 20 wherein the bacterium is Lactobacillus acidophilus. 23. The method of claim 18 wherein the protein aeroallergen is a protein component of a pollen, mold, animal dander, or insect. 24. The method of claim 1 or 18 wherein the bacterium can adhere to intestinal mucosa.

Details for Patent 7,060,687

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Greer Laboratories, Inc.	N/A	insects (whole body), mite dermatophagoides pteronyssinus	Injection	101835	09/15/1958		2040-01-28